Press release Konstantynów Łódzki, 23 December 2021

Mabion executes agreement with Novavax and produces first full batch of antigen for COVID-19 vaccine

Mabion, under its agreement with Novavax concluded on 8 October this year, has successfully and on schedule produced the first full batch of the protein antigen for the US partner. The production of this batch of the vaccine component was preceded by its acquisition several times as part of the processes covered by the first agreement with Novavax signed in March. Consequently, the desired high product quality is consistently achieved, which has been confirmed by tests performed in the company's laboratories and cross-confirmed in laboratories working for Novavax located in the United States and Europe.

Mabion is already beginning to recognise revenue from the production of its first full batch of product under a new agreement with Novavax signed in October. The total value of the contract for the provision of antigen to Novavax during its term, i.e. until the end of 2025, has been set at approximately PLN 1.5bn. The protein antigen is a key component of the Nuvaxovid vaccine, which was approved by the European Commission for use within the European Union on 20 December this year and previously received a positive opinion from the European Medicines Agency. In separate regulatory processes, the vaccine has received approval for use in the Philippines and Indonesia - the combined population of the two countries is more than 370 million people - as well as authorisation from the World Health Organisation for the conditional use of the vaccine produced under the name Covavax.

- As previously announced, commercial scale production for Novavax is on schedule. We have began production of the next batch, and we plan to produce more and more batches in the coming weeks, with the aim of reaching full capacity in the second quarter of 2022. We can say that we are running an exemplary operation on our section of the "frontline" against coronavirus. Not only is the process we execute very efficient, obtaining a significant amount of product, but we can also be proud of its high quality - all in accordance with the specifications required by Novavax. Our partner is responsible for subsequent stages of the vaccine marketing process," says Krzysztof Kaczmarczyk, President of the Management Board of Mabion S.A.

Information on Mabion S.A.

Mabion S.A. (WSE: MAB) is a fully integrated Polish biopharmaceutical company established in 2007, whose core business is the design and development of the latest generation of medicines based on recombinant protein technology (e.g., monoclonal antibodies). Mabion' expertise covers both the drug design phase and the selection of protein expression technologies, their purification, production activities in the GMP standard (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), the development of analytical tools (for structural, functional, physicochemical characteristcs), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company's most advanced project is MabionCD20, a biosimilar to MabThera (rituximab) with therapeutic indications for non-Hodgkin's lymphoma, leukaemia and rheumatoid arthritis (RA). In addition, since signing the contract with Novavax for commercial production of the vaccine on COVID-19 in October this year, Mabion has been developing and expanding its

existing platform to include CDMO activities, i.e. contract development services, GMP manufacturing and GMP/GLP analytical services across the full range of the above capabilities. Mabion is a public company listed on the Warsaw Stock Exchange. More information about the Company is available at www.mabion.eu.